Key result
High-adherence extended warfarin linked to ~77% lower recurrent VTE hospitalization, but more major bleeding.
Why the study?
Little was known about warfarin adherence patterns beyond 6 months of initial anticoagulation and their association with effectiveness and safety in patients with VTE.
Does extended treatment with warfarin and its specific adherence patterns reduce recurrent VTE hospitalization in patients who have completed initial anticoagulation?
Cohort (n=10,448)
Yes
Does extended treatment with warfarin and its specific adherence patterns reduce recurrent VTE hospitalization in patients who have completed initial anticoagulation?
Extended warfarin treatment with high adherence reduces recurrent VTE but increases the risk of major bleeding, highlighting the need to carefully weigh ongoing risks and benefits.
Answers are grounded in this paper and cite their sources.
High-adherence extended warfarin was associated with lower recurrent VTE hospitalization but higher bleeding; leaves open optimal duration strategies pending randomized data.
Background: Little is published about warfarin therapy adherence patterns beyond 6 months of initial anticoagulant treatment and their association with effectiveness and safety for patients with venous thromboembolism (VTE). Objectives: To compare the risks of recurrent VTE and major bleeding during extended treatment between adherence patterns using MarketScan Commercial and Medicare Supplemental databases (2013-2019). Methods: In a retrospective cohort study, we included patients with incident VTE who completed an initial 6-month anticoagulant treatment and received either warfarin or no extended therapy. Group-based trajectory models were used to identify distinct extended treatment trajectories. Associations between the trajectories and risk of hospitalization due to recurrent VTE and major bleeding were assessed using inverse probability treatment-weighted Cox proportional hazards models. Results: Compared with no extended treatment, consistently high warfarin adherence was associated with a significantly decreased risk of hospitalization due to recurrent VTE (hazard ratio [HR] = 0.23; 95% CI, 0.12-0.45), but gradually (HR = 0.29; 95CI, 0.08-1.06) or rapidly declining (HR = 0.14; 95% CI, 0.02-1.24) adherence showed no association with the risk of hospitalization due to recurrent VTE. Compared with no extended treatment, warfarin extended therapy was associated with an increased risk of hospitalization due to major bleeding regardless of adherence patterns (consistently high: HR = 2.08; 95% CI, 1.18-3.64, gradually declining: HR = 2.10; 95% CI, 0.74-5.95, and rapidly declining: HR = 9.19; 95% CI, 4.38-19.29). However, compared with rapidly declining adherence, consistently high (HR = 0.23; 95% CI, 0.11-0.47) and gradually declining (HR = 0.23; 95% CI, 0.08-0.64) adherence were associated with decreased risk of hospitalization due to major bleeding. Conclusion: The findings indicated that consistently high adherence to extended warfarin treatment was associated with a decreased risk of hospitalization due to recurrent VTE but an increased risk of hospitalization due to major bleeding compared with no extended treatment.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2023) conducted a cohort in Venous thromboembolism (VTE) (n=10,448). Extended warfarin treatment (consistently high adherence) vs. No extended treatment was evaluated on First hospitalization due to recurrent VTE (HR 0.23, 95% CI 0.12-0.45). Consistently high adherence to extended warfarin treatment reduced the risk of hospitalization for recurrent VTE compared to no extended treatment, but increased the risk of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: